Go to navigation
Go to content
Astrazeneca Worldwide
AstraZeneca Worldwide
Search
Main navigation
Home
Our medicines
Diseases and conditions
Community support
Help affording your medicines
Research & development
Healthcare professionals
Careers
About AstraZeneca US
Our company
AZ on the issues
Investors
Corporate responsibility
Newsroom
All news
Corporate news
Financial news
Product news
Research news
Media resources
US web sites
Contact us
You are here
Home
About AstraZeneca US
Newsroom
Product news
The following shows headlines of all product-related news articles published within 12-months, starting from most recent.
Subscribe to RSS news feed
Pages
1
2
Next
News search
Date
Jul 1, 2008
Summary Judgment granted for SEROQUEL® patent litigation
Jun 4, 2008
AstraZeneca submits an sNDA for SYMBICORT® for the treatment of asthma in children as young as age six
May 30, 2008
AstraZeneca submits sNDA for NEXIUM® I.V. for peptic ulcer bleed indication
May 20, 2008
Study analyzed SYMBICORT® in children with persistent asthma
May 20, 2008
New patient satisfaction study with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy in adults with asthma
May 14, 2008
FDA approves AstraZeneca’s SEROQUEL® for maintenance treatment in bipolar disorder
May 8, 2008
AstraZeneca submits sNDA for SEROQUEL XR™ for the treatment of generalized anxiety disorder – a first for the atypical antipsychotic class of medicines
May 5, 2008
New data on SEROQUEL XR™ in treatment of both major depressive disorder and generalized anxiety disorder presented at APA Annual Meeting
Apr 30, 2008
AstraZeneca submits an sNDA for SYMBICORT® for COPD indication
Apr 15, 2008
AstraZeneca settles US NEXIUM® patent litigation with Ranbaxy
Mar 18, 2008
Study compares bronchodilatory effects of SYMBICORT® and ADVAIR® in adults with asthma
Mar 17, 2008
Study analyzed long-term SYMBICORT® use in children with persistent asthma
Feb 29, 2008
AstraZeneca submits sNDA for SEROQUEL XR™ for the treatment of major depressive disorder
Feb 28, 2008
FDA approves NEXIUM® for the treatment of short-term GERD in children 1 To 11 years old
Jan 2, 2008
AstraZeneca submits sNDAs for SEROQUEL XR™ for the treatment of bipolar mania and bipolar depression
Dec 14, 2007
Data show ARIMIDEX® (anastrozole) continues to be superior to Tamoxifen in helping reduce the risk of recurrence in patients with early breast cancer
Dec 10, 2007
FDA concludes there is no increased risk of cardiac events for patients treated with omeprazole and NEXIUM® (esomeprazole magnesium).
Nov 29, 2007
AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX® (anastrozole) from the FDA
Nov 16, 2007
SEROQUEL XR™ receives approval from FDA for maintenance treatment of schizophrenia
Nov 9, 2007
CRESTOR® now indicated to slow the progression of atherosclerosis in patients with elevated cholesterol
Pages
1
2
Next
Page tools
Print
Bookmark this page
Who is AstraZeneca?
Watch this short video to learn who we are and what we do